Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation

被引:34
作者
Garcia Linaresa, Guadalupe
Gismondi, Santiago
Osa Codesido, Nicolas
Moreno, Silvia N. J.
Docampo, Roberto
Rodriguez, Juan B.
机构
[1] Univ Buenos Aires, Dept Quim Organ, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Fac Ciencias Exactas & Nat, UMYMFOR CONICET FCEyN, RA-C1428EHA Buenos Aires, DF, Argentina
[3] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA
[4] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA
关键词
Chagas' disease; Trypanosoma cruzi; Toxoplasma gondii; aryloxyethyl thiocyanates; squalene synthase;
D O I
10.1016/j.bmcl.2007.07.012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
As a part of our project aimed at developing new safe chemotherapeutic and chemoprophylactic agents against tropical diseases, fluorine-containing drugs structurally related to 4-phenoxyphenoxyethyl thiocyanate (1) were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the parasite responsible of American trypanosomiasis (Chagas' disease), and Toxoplasma gondii, the etiological agent of toxoplasmosis. This thiocyanate derivative had previously proven to be an effective agent against T cruzi proliferation. Fluorine-containing thiocyanate derivatives 2 and 3 were threefold more potent than our lead drug I against intracellular T Cruzi. The biological evaluation against T gondii was also very promising. The IC50 values corresponding to 2 and 3 were at the very low micromolar level against tachyzoites of T. gondii. Both of these drugs are interesting examples of effective antiparasitic agents that have outstanding potential not only as lead drugs but also to be used for further in vivo studies. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5068 / 5071
页数:4
相关论文
共 40 条
[1]   Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents [J].
Augustyns, K ;
Amssoms, K ;
Yamani, A ;
Rajan, PK ;
Haemers, A .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (12) :1117-1141
[2]   BIOLOGY OF TRYPANOSOMA-CRUZI [J].
BRENER, Z .
ANNUAL REVIEW OF MICROBIOLOGY, 1973, 27 :347-382
[3]   The major cysteine proteinase of Trypanosoma cruzi:: A valid target for chemotherapy of Chagas disease [J].
Cazzulo, JJ ;
Stoka, V ;
Turk, V .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (12) :1143-1156
[4]   New N- and O-arylations with phenylboronic acids and cupric acetate [J].
Chan, DMT ;
Monaco, KL ;
Wang, RP ;
Winters, MP .
TETRAHEDRON LETTERS, 1998, 39 (19) :2933-2936
[5]   Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi [J].
Cinque, GM ;
Szajnman, SH ;
Zhong, L ;
Docampo, R ;
Schvartzapel, AJ ;
Rodriguez, JB ;
Gros, EG .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (09) :1540-1554
[6]   Antiproliferative synergism of azasterols and antifolates against Toxoplasma gondii [J].
Dantas-Leite, L ;
Urbina, JA ;
de Souza, W ;
Vommaro, RC .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (02) :130-135
[7]   Selective anti-Toxoplasma gondii activities of azasterols [J].
Dantas-Leite, L ;
Urbina, JA ;
de Souza, W ;
Vommaro, RC .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (06) :620-626
[8]   Glycoinositolphospholipids, free and as anchors of proteins, in Trypanosoma cruzi [J].
de Lederkremer, RM ;
Bertello, LE .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (12) :1165-1179
[9]   THE CHALLENGE OF CHAGAS-DISEASE CHEMOTHERAPY - AN UPDATE OF DRUGS ASSAYED AGAINST TRYPANOSOMA-CRUZI [J].
DECASTRO, SL .
ACTA TROPICA, 1993, 53 (02) :83-98
[10]   CELL BIOLOGY OF TRYPANOSOMA-CRUZI [J].
DESOUZA, W .
INTERNATIONAL REVIEW OF CYTOLOGY-A SURVEY OF CELL BIOLOGY, 1984, 86 :197-283